Published in Lancet on May 18, 2010
New vaccines for tuberculosis. Lancet (2010) 2.14
Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly. Immunity (2012) 2.08
Ontogeny of Toll-like receptor mediated cytokine responses of human blood mononuclear cells. PLoS One (2010) 1.66
Incipient and subclinical tuberculosis: defining early disease states in the context of host immune response. J Infect Dis (2011) 1.66
Two-thirds of smear-positive tuberculosis cases in the community were undiagnosed in Northwest Ethiopia: population based cross-sectional study. PLoS One (2011) 1.53
Adverse Outcomes after Non-Chest Surgeries in Patients with Pulmonary Tuberculosis: A Nationwide Study. PLoS One (2015) 1.41
Biomarker correlates of survival in pediatric patients with Ebola virus disease. Emerg Infect Dis (2014) 1.30
Antibody-mediated immunity against tuberculosis: implications for vaccine development. Cell Host Microbe (2013) 1.26
Pathology of post primary tuberculosis of the lung: an illustrated critical review. Tuberculosis (Edinb) (2011) 1.25
Pulmonary tuberculosis in severely-malnourished or HIV-infected children with pneumonia: a review. J Health Popul Nutr (2013) 1.18
Epidemiology and disease burden of tuberculosis in children: a global perspective. Infect Drug Resist (2014) 1.16
Challenges in the Management of HIV-Infected Malnourished Children in Sub-Saharan Africa. AIDS Res Treat (2012) 1.14
The ongoing challenge of latent tuberculosis. Philos Trans R Soc Lond B Biol Sci (2014) 1.12
Tuberculosis vaccines and prevention of infection. Microbiol Mol Biol Rev (2014) 1.03
Tuberculosis and HIV co-infection in children. BMC Infect Dis (2014) 1.00
Outcomes of comprehensive care for children empirically treated for multidrug-resistant tuberculosis in a setting of high HIV prevalence. PLoS One (2012) 1.00
B cells and antibodies in the defense against Mycobacterium tuberculosis infection. Immunol Rev (2015) 0.97
Tuberculosis in ageing: high rates, complex diagnosis and poor clinical outcomes. Age Ageing (2012) 0.97
The immunologic basis for severe neonatal herpes disease and potential strategies for therapeutic intervention. Clin Dev Immunol (2013) 0.93
Age-related changes in expression and function of Toll-like receptors in human skin. Development (2012) 0.88
Childhood tuberculosis in northern Viet Nam: a review of 103 cases. PLoS One (2014) 0.86
Exploration of ecological factors related to the spatial heterogeneity of tuberculosis prevalence in P. R. China. Glob Health Action (2014) 0.86
Year of birth effects in the historical decline of tuberculosis mortality: a reconsideration. PLoS One (2013) 0.83
Effects of gender and age on development of concurrent extrapulmonary tuberculosis in patients with pulmonary tuberculosis: a population based study. PLoS One (2013) 0.83
Low case notification rates of childhood tuberculosis in southern Ethiopia. BMC Pediatr (2015) 0.81
Features of Adolescents Tuberculosis at a Referral TB's Hospital in Tehran, Iran. Mediterr J Hematol Infect Dis (2016) 0.81
Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy. BMC Med (2016) 0.80
Role of B cells and antibodies in acquired immunity against Mycobacterium tuberculosis. Cold Spring Harb Perspect Med (2014) 0.80
Antibody responses to mycobacterial antigens in children with tuberculosis: challenges and potential diagnostic value. Clin Vaccine Immunol (2012) 0.78
Exploring the sociodemographic and clinical features of extrapulmonary tuberculosis in saudi arabia. PLoS One (2015) 0.77
The Bandim TBscore--reliability, further development, and evaluation of potential uses. Glob Health Action (2014) 0.77
Trends of sputum-smear positive tuberculosis in Zimbabwe: 2008-2011. BMC Res Notes (2015) 0.75
HIV-TB co-infection in children: associated factors and access to HIV services in Lagos, Nigeria. Public Health Action (2015) 0.75
Sociodemographic, Epidemiological, and Clinical Risk Factors for Childhood Pulmonary Tuberculosis in Severely Malnourished Children Presenting With Pneumonia: Observation in an Urban Hospital in Bangladesh. Glob Pediatr Health (2015) 0.75
Why the Convention on the Rights of the Child must become a guiding framework for the realization of the rights of children affected by tuberculosis. BMC Int Health Hum Rights (2016) 0.75
Treatment Outcomes for Adolescents With Multidrug-Resistant Tuberculosis in Lima, Peru. Glob Pediatr Health (2016) 0.75
Deaths during tuberculosis treatment among paediatric patients in a large tertiary hospital in Nigeria. PLoS One (2017) 0.75
Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet (2012) 6.78
A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature (2004) 6.29
Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med (2012) 5.87
Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun (2008) 4.93
The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem (2004) 4.75
PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science (2008) 4.74
Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. J Infect Dis (2012) 4.60
A critical review of interventions to redress the inequitable distribution of healthcare professionals to rural and remote areas. Rural Remote Health (2009) 4.53
Confronting the scientific obstacles to global control of tuberculosis. J Clin Invest (2008) 4.41
Tuberculosis - metabolism and respiration in the absence of growth. Nat Rev Microbiol (2005) 4.38
Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science (2011) 4.13
Tuberculosis in children. N Engl J Med (2012) 4.07
Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2005) 3.97
Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science (2009) 3.73
DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis. Cell (2003) 3.36
Tuberculosis: what we don't know can, and does, hurt us. Science (2010) 3.29
Interventions for increasing the proportion of health professionals practising in rural and other underserved areas. Cochrane Database Syst Rev (2009) 3.20
The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine (2006) 3.16
Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis (2013) 3.12
Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun (2003) 3.01
Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance. Infect Immun (2005) 2.89
Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis (2010) 2.86
Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest (2009) 2.78
Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J Comb Chem (2003) 2.63
The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc Natl Acad Sci U S A (2003) 2.60
Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients. J Infect Dis (2012) 2.53
Virulence of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli. J Infect Dis (2005) 2.50
Differential monocyte activation underlies strain-specific Mycobacterium tuberculosis pathogenesis. Infect Immun (2004) 2.47
The W-Beijing lineage of Mycobacterium tuberculosis overproduces triglycerides and has the DosR dormancy regulon constitutively upregulated. J Bacteriol (2007) 2.42
SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2012) 2.41
Rationally designed nucleoside antibiotics that inhibit siderophore biosynthesis of Mycobacterium tuberculosis. J Med Chem (2006) 2.37
Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis (2013) 2.16
Proteasomal protein degradation in Mycobacteria is dependent upon a prokaryotic ubiquitin-like protein. J Biol Chem (2008) 2.12
The role of MmpL8 in sulfatide biogenesis and virulence of Mycobacterium tuberculosis. J Biol Chem (2004) 1.99
Prospects for new antitubercular drugs. Curr Opin Microbiol (2004) 1.94
Hypoxic response of Mycobacterium tuberculosis studied by metabolic labeling and proteome analysis of cellular and extracellular proteins. J Bacteriol (2002) 1.86
Culture-confirmed childhood tuberculosis in Cape Town, South Africa: a review of 596 cases. BMC Infect Dis (2007) 1.72
Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis (2008) 1.67
High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal Chem (2011) 1.64
Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms. J Immunol (2013) 1.62
Biosynthesis and recycling of nicotinamide cofactors in mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli. J Biol Chem (2008) 1.62
Unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis. J Biol Chem (2003) 1.62
A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis. ACS Chem Biol (2012) 1.59
A comparative lipidomics platform for chemotaxonomic analysis of Mycobacterium tuberculosis. Chem Biol (2011) 1.56
Can social interventions prevent tuberculosis?: the Papworth experiment (1918-1943) revisited. Am J Respir Crit Care Med (2012) 1.55
The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol (2009) 1.53
Xpert MTB/RIF for rapid diagnosis of tuberculous lymphadenitis from fine-needle-aspiration biopsy specimens. J Clin Microbiol (2011) 1.53
Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. J Bacteriol (2002) 1.52
Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother (2011) 1.50
Genetic diversity of Mycobacterium tuberculosis isolates from a tertiary care tuberculosis hospital in South Korea. J Clin Microbiol (2009) 1.49
Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on anti-retroviral therapy. BMC Pediatr (2008) 1.49
Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc Natl Acad Sci U S A (2012) 1.48
Fumarate reductase activity maintains an energized membrane in anaerobic Mycobacterium tuberculosis. PLoS Pathog (2011) 1.45
Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev (2015) 1.45
Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis. Science (2012) 1.44
Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosis. J Clin Microbiol (2009) 1.43
Top down characterization of secreted proteins from Mycobacterium tuberculosis by electron capture dissociation mass spectrometry. J Am Soc Mass Spectrom (2003) 1.41
Antitubercular nucleosides that inhibit siderophore biosynthesis: SAR of the glycosyl domain. J Med Chem (2006) 1.41
Management of multidrug-resistant tuberculosis in children: a survival guide for paediatricians. Paediatr Respir Rev (2010) 1.41
Inhibition of siderophore biosynthesis in Mycobacterium tuberculosis with nucleoside bisubstrate analogues: structure-activity relationships of the nucleobase domain of 5'-O-[N-(salicyl)sulfamoyl]adenosine. J Med Chem (2008) 1.40
5'-O-[(N-acyl)sulfamoyl]adenosines as antitubercular agents that inhibit MbtA: an adenylation enzyme required for siderophore biosynthesis of the mycobactins. J Med Chem (2007) 1.39
A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence. Proc Natl Acad Sci U S A (2013) 1.39
In vivo phenotypic dominance in mouse mixed infections with Mycobacterium tuberculosis clinical isolates. J Infect Dis (2005) 1.36
Impact of diabetes and smoking on mortality in tuberculosis. PLoS One (2013) 1.36
Resistant Mycobacterium bovis Bacillus Calmette-Guérin disease: implications for management of Bacillus Calmette-Guérin Disease in human immunodeficiency virus-infected children. Pediatr Infect Dis J (2004) 1.36
Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting. Thorax (2012) 1.34
Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [¹⁸F]2-fluoro-deoxy-D-glucose positron emission tomography and computed tomography. Antimicrob Agents Chemother (2012) 1.32
Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PLoS One (2013) 1.31
Expansion of the mycobacterial "PUPylome". Mol Biosyst (2009) 1.31
Meropenem inhibits D,D-carboxypeptidase activity in Mycobacterium tuberculosis. Mol Microbiol (2012) 1.30
Rapid detection of fluoroquinolone-resistant and heteroresistant Mycobacterium tuberculosis by use of sloppy molecular beacons and dual melting-temperature codes in a real-time PCR assay. J Clin Microbiol (2010) 1.30
Childhood drug-resistant tuberculosis in the Western Cape Province of South Africa. Acta Paediatr (2006) 1.29
Mutations in gidB confer low-level streptomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2011) 1.29
Evaluating the sensitivity of Mycobacterium tuberculosis to biotin deprivation using regulated gene expression. PLoS Pathog (2011) 1.29
Design, synthesis, and biological evaluation of beta-ketosulfonamide adenylation inhibitors as potential antitubercular agents. Org Lett (2006) 1.27
Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol (2012) 1.27
Expression, production and release of the Eis protein by Mycobacterium tuberculosis during infection of macrophages and its effect on cytokine secretion. Microbiology (2007) 1.26
Treatment of Tuberculosis. N Engl J Med (2015) 1.25
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. Bioorg Med Chem Lett (2013) 1.25
Uptake of unnatural trehalose analogs as a reporter for Mycobacterium tuberculosis. Nat Chem Biol (2011) 1.23
Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother (2012) 1.22
A community-based tuberculosis program in Cambodia. JAMA (2004) 1.21
The three RelE homologs of Mycobacterium tuberculosis have individual, drug-specific effects on bacterial antibiotic tolerance. J Bacteriol (2010) 1.21
Inhibition of siderophore biosynthesis by 2-triazole substituted analogues of 5'-O-[N-(salicyl)sulfamoyl]adenosine: antibacterial nucleosides effective against Mycobacterium tuberculosis. J Med Chem (2008) 1.21
Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies. Drug Discov Today (2011) 1.21
Surveillance of antituberculosis drug resistance among children from the Western Cape Province of South Africa--an upward trend. Am J Public Health (2009) 1.21
Paediatric use of second-line anti-tuberculosis agents: a review. Tuberculosis (Edinb) (2011) 1.19
Differential virulence and disease progression following Mycobacterium tuberculosis complex infection of the common marmoset (Callithrix jacchus). Infect Immun (2013) 1.16
Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles. J Med Chem (2009) 1.15
Lipidomic discovery of deoxysiderophores reveals a revised mycobactin biosynthesis pathway in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2012) 1.13
Pathway-selective sensitization of Mycobacterium tuberculosis for target-based whole-cell screening. Chem Biol (2012) 1.13
Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis. Curr Clin Pharmacol (2010) 1.12
HIV-associated tuberculous meningitis--diagnostic and therapeutic challenges. Tuberculosis (Edinb) (2010) 1.12
Defining the mode of action of tetramic acid antibacterials derived from Pseudomonas aeruginosa quorum sensing signals. J Am Chem Soc (2009) 1.12
Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second-line drugs. Antimicrob Agents Chemother (2013) 1.10
BacA, an ABC transporter involved in maintenance of chronic murine infections with Mycobacterium tuberculosis. J Bacteriol (2008) 1.10
Mycobacterium leprae is naturally resistant to PA-824. Antimicrob Agents Chemother (2006) 1.09
Bisubstrate adenylation inhibitors of biotin protein ligase from Mycobacterium tuberculosis. Chem Biol (2011) 1.08